Int J Clin Pract 60:896–905CrossRefPubMed 23. Gold DT, Safi W, Trinh H (2006) Patient preference and adherence: comparative US studies between two bisphosphonates, weekly risedronate Everolimus and monthly ibandronate. Curr Med Res Opin 22:2383–2391CrossRefPubMed 24. Bouee S, Charlemagne
A, Fagnani F, Le Jeunne P, Sermet C, Naudin F, Lancry PJ (2004) Changes in osteoarthritis management by general practitioners in the COX2-inhibitor era-concomitant gastroprotective therapy. Joint Bone Spine 71:214–220CrossRefPubMed 25. Rosen CJ, Hochberg MC, Bonnick SL, McClung M, Miller P, Broy S, Kagan R, Chen E, Petruschke RA, Thompson DE, de Papp AE (2005) Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with Rapamycin cell line postmenopausal osteoporosis: a randomized double-blind study. J Bone Miner Res 20:141–151CrossRefPubMed 26. McCombs JS, Thiebaud P, McLaughlin-Miley C, Shi J (2004) Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas 48:271–287CrossRefPubMed 27. Brankin E, Walker M, Lynch N, Aspray T, Lis Y, Cowell W (2006) The impact
of dosing frequency on compliance and persistence with bisphosphonates among postmenopausal women in the UK: evidence from three databases. Curr Med Res Opin 22:1249–1256CrossRefPubMed 28. Lynch N, Walker M, Cowell W, Suppapanya N, Hammerschmidt T, Rigney U (2005) An international comparison of the impact of dosing frequency on adherence with bisphosphonate therapy among postmenopausal women in the UK and Germany. J Bone Miner Res 21:S180 29. Silverman S, Chesnut C, Amonkar M, Cziraky M, Barr C (2006) Improved persistence in women treated with once-monthly ibandronate versus weekly biphosphonates: a first look. J Bone Miner Res 22:SU355 30. Rosenbaum P, Rubin D (1983) The central role of the propensity score in observational studied for causal effects. Biometrika 70:41–55CrossRef 31. Cotte FE, Mercier F, De Pouvourville G (2008) Relationship between compliance and persistence with osteoporosis medications and fracture risk in primary health care in France: a retrospective case–control analysis. Clin Ther
30:2410–2422CrossRefPubMed 32. Adachi J, Lynch N, Middelhoven H, Hunjan M, Cowell W (2007) The association between compliance and persistence with bisphosphonate check details therapy and fracture risk: a review. BMC Musculoskelet Disord 8:97CrossRefPubMed 33. Siris ES, Harris ST, Rosen CJ, Barr CE, AC220 mouse Arvesen JN, Abbott TA, Silverman S (2006) Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 81:1013–1022CrossRefPubMed 34. Blouin J, Dragomir A, Moride Y, Ste-Marie LG, Fernandes JC, Perreault S (2008) Impact of noncompliance with alendronate and risedronate on the incidence of nonvertebral osteoporotic fractures in elderly women. Br J Clin Pharmacol 66:117–127CrossRefPubMed 35.